Beta Bionics Closes $172.5M Offering After Underwriters Exercise Full Option
BBNX has more than doubled off its 52-week low of $8.8 on elevated volume (2.4× avg).
Summary
Beta Bionics closed its public offering, raising $172.5 million in gross proceeds after underwriters exercised their full option to purchase an additional 1.3 million shares. The offering included 7.65 million shares at $17.25 and pre-funded warrants for 1.04 million shares. This follows the upsized $150 million deal announced on September 16; the full option exercise adds $22.5 million. Proceeds will fund commercialization of the Mint patch pump, manufacturing expansion, and general corporate purposes. The offering was priced at a discount to the prior close, reflecting typical dilution for a growth-stage medtech.
At the time of this announcement, BBNX was trading at $21.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $964.1M. The 52-week trading range was $8.80 to $32.71. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.